Multicentric Observational Prospective Study on the Use of the EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke
Status: Unknown
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY
The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Signed Informed Consent Form
• Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1
• ASPECTS ≥ 6
• Mismatch or good collaterals showed at MR or multiphasic CTA or pCT
• Groin Puncture performed within 12 hours from symptom onset
• Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment
Locations
Other Locations
Italy
ASST GOM Niguarda
RECRUITING
Milan
Contact Information
Primary
Edoardo Boccardi, MD
edoardo.bocccardi@ospedaleniguarda.it
00396444
Backup
Luca Valvassori, MD
luca.valvassori@gmail.com
00396444
Time Frame
Start Date: 2022-01-01
Completion Date: 2024-06-15
Participants
Target number of participants: 100
Treatments
EmboTrap ® II Device
The study group consists of the patients with acute ischemic stroke from large vessel occlusion treated with EmboTrap ® II Device (Neuravi)
Related Therapeutic Areas
Sponsors
Leads: Niguarda Hospital
Collaborators: Neuravi Limited